Johnson & Johnson (JNJ) earnings Q3 2026
Johnson & Johnson reported a slightly higher-than-expected profit on Tuesday, driven by strong sales of its immune disease…
Novo Nordisk CEO on rebuilding investor trust after backlash
Novo Nordisk CEO Maziar Mike Doustdar waits for the start of the pharmaceutical company’s annual general meeting in…
Meet Ottava, J&J’s surgical robot leading the healthcare giant into a lucrative new market
Johnson & Johnson is diving head-first into the deep end of the competitive robotic surgery market. The payoff…
This medical device stock looks like a gift for patient investors
Insulet is a high-quality compounder where a temporary execution issue is masking strong underlying fundamentals. Type 2 diabetes…
We’re increasing our Eli Lilly price target after another beat-and-raise quarter
Eli Lilly on Wednesday reported better-than-expected quarterly results and raised its full-year guidance as the company’s portfolio of…
J&J falls despite a beat-and-raise quarter. Why we’re raising our price target anyways
Johnson & Johnson shares fell Tuesday despite a mostly strong second-quarter earnings report and an increase to its…
Johnson & Johnson has a chance to show it’s more than just a rotation winner
Johnson & Johnson shares have showed signs of life ahead of earnings. For the stock to keep running,…